Yanyan Lou

机构：Centre National de la Recherche Scientifique, Shenzhen University, WinnMed, Mayo Clinic in Arizona, Mayo Clinic Hospital, Modèles Insectes de l'Immunité Innée, Shenzhen Luohu People's Hospital, Mayo Clinic in Florida, Institut de Biologie Moléculaire et Cellulaire, Université de Strasbourg, Guangzhou Medical University · ORCID：0000-0001-6207-9461

发表论文 292 篇 · 总被引 8798 次 · h-index 43

代表论文

• TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). (2025 · Journal of Clinical Oncology · 被引 21)
• Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution (2025 · Current Oncology Reports · 被引 13)
• Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC (2025 · Nature Communications · 被引 8)
• Datopotamab Deruxtecan Plus Pembrolizumab With or Without Platinum-Based Chemotherapy for Advanced or Metastatic NSCLC: The Phase Ib TROPION-Lung02 Trial (2026 · Journal of Thoracic Oncology · 被引 6)
• Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer (2026 · Journal of Clinical Oncology · 被引 2)
• A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity (2026 · Journal of Translational Medicine · 被引 2)